Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs ProShares UltraPro QQQ ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while ProShares UltraPro QQQ ETF trades at $71.87 (market cap $38.26B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 5.1× Spyre Therapeutics Inc. Common Stock's market cap, and ProShares UltraPro QQQ ETF is more actively traded (38,965,303 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro QQQ ETF for 25 Days on average.
| SYRE | TQQQ | |
|---|---|---|
Market Cap | $7.52B | $38.26B |
Volume | 1,441,031 | 38,965,303 |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.92 | $87.22 |
52-Week Low | $22.18 | $37.89 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TQQQ trades at $78.81, down 1.0% on the day, with a bullish technical signal from moving averages but neutral oscillators. The leveraged ETF faces mixed sentiment with recent articles highlighting both strong performance during the AI boom and concerns about hidden costs and volatility decay. Support levels are established at $77-$79, with resistance at $81-$82.
The outlook remains volatile with 3x leverage amplifying both gains and losses. Key risks include expense ratios beyond the stated 0.82% and market volatility amplification. Institutional activity shows mixed positioning, with some firms reducing stakes while others add exposure to tech and AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
